Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
Monopar Therapeutics Inc. (MNPR)
Company Research
Source: GlobeNewswire
WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the closing of its previously announced best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. Janus Henderson Investors, RA Capital Management, L.P. and other notable growth and life science investors participated in the offering. Rodman & Renshaw LLC acted as the exclusive placement agent for the offering. Monopar Therapeutics intends to use the net proceeds from the offering for general corporate purposes, which may include research and development expenditures, clinical trial expenditures, manufact
Show less
Read more
Impact Snapshot
Event Time:
MNPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNPR alerts
High impacting Monopar Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
MNPR
News
- Monopar Therapeutics Inc. (NASDAQ: MNPR) had its price target raised by analysts at HC Wainwright from $6.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent DevelopmentsGlobeNewswire
- Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
- Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common StockGlobeNewswire
- Monopar Therapeutics Inc. Announces Proposed Public Offering of Common StockGlobeNewswire
MNPR
Sec Filings
- 11/8/24 - Form 8-K
- 11/8/24 - Form 10-Q
- 11/6/24 - Form SC
- MNPR's page on the SEC website